Antisense remains on track to positive clinical trial results
Mar 18, 2020
Next Investors
Mar 18, 2020 |
1 min
The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.
Antisense appoints experienced biotech executive
Feb 28, 2020
Next Investors
Feb 28, 2020 |
3 min
Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.
ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations
Dec 19, 2019
Next Investors
Dec 19, 2019 |
15 min
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Rat's rant: What's hot, what's not and ... Jimi Hendrix
Sep 19, 2019
Next Investors
Sep 19, 2019 |
18 min
Some of today’s stocks would love to be as hot as Jimi Hendrix in his prime. That’s certainly what they are aiming for.
Antisense Phase II Clinical Trial now 50% enrolled and on track for completion
Jan 21, 2019
Next Investors
Jan 21, 2019 |
2 min
Antisense Therapeutics (ASX:ANP) has provided a highly promising update on its Phase II clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD).
